ARIDOL KIT

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

MANNITOL; MANNITOL; MANNITOL; MANNITOL

可用日期:

PHARMAXIS LTD

ATC代码:

V04CX

INN（国际名称）:

OTHER DIAGNOSTIC AGENTS

剂量:

5MG; 10MG; 20MG; 40MG

药物剂型:

KIT

组成:

MANNITOL 5MG; MANNITOL 10MG; MANNITOL 20MG; MANNITOL 40MG

给药途径:

INHALATION

每包单位数:

15G/50G

处方类型:

Prescription Recommended

治疗领域:

DIAGNOSTIC AGENTS

產品總結:

Active ingredient group (AIG) number: 0461510001; AHFS:

授权状态:

APPROVED

授权日期:

2019-06-13

产品特点

_Pr_
_Aridol_
®
_ Product Monograph _
_Page 1 of 29_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ARIDOL
®
Mannitol Inhalation Powder
Inhalation Powder, Capsules of 0 mg, 5 mg, 10 mg, 20 mg or 40 mg, Oral
Inhalation
Diagnostic Agent to Assess Bronchial Hyperresponsiveness
ATC Code: V04CX
Pharmaxis Ltd
20 Rodborough Rd
Frenchs Forest ,2086
Australia
Imported and Distributed by:
Methapharm Inc
81 Sinclair Boulevard
Brantford, ON N3S 7X6
Canada
Date of Initial Approval:
June 12, 2019
Submission Control No: 217446
_Pr_
_Aridol_
®
_ Product Monograph _
_Page 2 of 29_
TABLE OF CONTENTS
PR
ARIDOL
® ................................................................................................................................
1
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................... 4
1
INDICATIONS
...............................................................................................................
4
1.1
Pediatrics
................................................................................................................
4
1.2
Geriatrics
................................................................................................................
4
2
CONTRAINDICATIONS
................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
...................................................... 4
4
DOSAGE AND ADMINISTRATION
...............................................................................
5
4.1
Dosing Considerations
............................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
........................................................ 5
4.3
Administration
.........................................................................................................
5
5
OVERDOSAGE
...........................................................................................................
13
6
DOSAGE